Abstract
Background Determination of cardiac output (CO) is essential to the clinical management of cardiovascular compromise. However, the invasiveness, procedural risks, and reliance on specialized infrastructure limit accessibility and scalability of standard-of-care right heart catheterization (RHC). Seismocardiography (SCG), a non-invasive technique which records subtle chest wall vibrations generated by cardiac mechanical activity, may offer a promising alternative for CO determination.
Objectives To develop and evaluate a deep learning model for estimating CO directly from SCG, electrocardiogram (ECG), and body mass index (BMI) in heart failure patients undergoing RHC.
Methods We trained a deep convolutional neural network for CO estimation using an open-access dataset comprising 73 heart failure patients with simultaneous RHC, SCG, and ECG recordings. Model performance was evaluated using a rotating leave-pair-out cross-validation strategy.
Results When estimating CO, the deep learning model achieved a mean bias of -0.35 L/min with limits of agreement (LoA) from -2.21 to 1.51 L/min. When predicting cardiac index in patients with a reference index < 2.2 L/min/m2, the model yielded a mean bias of 0.07 L/min/m2 with LoA from -0.35 to 0.48 L/min/m2.
Conclusions This study demonstrates the feasibility of using deep learning in combination with wearable SCG sensors to non-invasively estimate CO. Model performance was particularly strong in low-output states. These findings highlight the potential of SCG-based monitoring to augment clinical decision-making in settings where invasive measurements are impractical or unavailable. Prospective multicenter validation is needed to confirm generalizability and assess clinical impact.
Sources of Support This work was supported by NIH grants T32 HL129964 (N.J.K.), K08 ES037420 (N.J.K.), R01 HL124021 (S.Y.C.), R01 HL122596 (S.Y.C.); R01 HL151228 (S.Y.C.); the McKamish Family Foundation, the Hemophilia Center of Western Pennsylvania, and the Institute for Transfusion Medicine (N.J.K.), United Therapeutics Jenesis Innovative Research Award (N.J.K.), and the Pulmonary Hypertension Association (N.J.K.).
Disclosures S.Y.C. has served as a consultant for Merck, Janssen, and United Therapeutics; S.Y.C. is a director, officer, and shareholder in Synhale Therapeutics and Amlysion Therapeutics; S.Y.C. and N.J.K. hold research grants from United Therapeutics; S.Y.C. holds research grants from Bayer and the WoodNext Foundation. S.Y.C. has filed patent applications regarding the targeting of metabolism in pulmonary hypertension. Other authors: none.
Twitter Summary We developed a deep learning model to non-invasively estimate cardiac output from wearable seismocardiogram (SCG) signals in patients undergoing right heart catheterization. This is the largest study to date using SCG for noninvasive cardiac output monitoring. #HeartFailure, #WearableTech, #AIInCardiology.
Competing Interest Statement
S.Y.C. has served as a consultant for Merck, Janssen, and United Therapeutics; S.Y.C. is a director, officer, and shareholder in Synhale Therapeutics and Amlysion Therapeutics; S.Y.C. and N.J.K. hold research grants from United Therapeutics; S.Y.C. holds research grants from Bayer and the WoodNext Foundation. S.Y.C. has filed patent applications regarding the targeting of metabolism in pulmonary hypertension. Other authors: none.
Funding Statement
This work was supported by NIH grants T32 HL129964 (N.J.K.), K08 ES037420 (N.J.K.), R01 HL124021 (S.Y.C.), R01 HL122596 (S.Y.C.); R01 HL151228 (S.Y.C.); the McKamish Family Foundation, the Hemophilia Center of Western Pennsylvania, and the Institute for Transfusion Medicine (N.J.K.), United Therapeutics Jenesis Innovative Research Award (N.J.K.), and the Pulmonary Hypertension Association (N.J.K.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data was were originally located at: https://physionet.org/content/scg-rhc-wearable-database/1.0.0/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The code used for model development and analysis is publicly available at https://github.com/jwang6174/scg-co.
Abbreviations
- CI
- Cardiac index
- CInt
- Confidence interval
- CO
- Cardiac output
- LoA
- Limits of agreement
- LPOCV
- Leave-pair-out cross-validation
- PCC
- Pearson correlation coefficient
- RHC
- Right heart catheterization
- RMSE
- Root mean squared error
- SCG
- Seismocardiogram
- TD
- Thermodilution
